Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27 February 2023 purchased 200,000 shares in HBC at a price of NOK 2.69 per share.
Please see the attached notification form for further information.
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.
Attachment
![](https://ml-eu.globenewswire.com/media/N2I0NWVjZmMtZmUzYy00ZjVmLTg3MGYtYTk2NDZjOGYzMWFhLTEwMTI2Mjk=/tiny/Hofseth-Biocare-ASA.png)